Evidence map›Paper›PMID 25614221›Full record

ReviewNature reviews. Drug discovery2015

The re-emergence of natural products for drug discovery in the genomics era.

Alan L Harvey, RuAngelie Edrada-Ebel, Ronald J Quinn

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Drug discovery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 912 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
912citing papers in PubMed, 1 pooled it
203.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

912 citing papers in PubMed, 1 synthesis or guideline pooled it, 2,473 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Materials today. Bio · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. From Claims to Evidence: Re-Evaluating the Molecular Pharmacology ofInternational journal of molecular sciences · 2026
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. SuFEx-Enabled Reprogramming of Flavonoids for Selective α-Glucosidase Covalent Inhibition.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  18. Review
  19. Phytochemical Profile and Biological Activities ofPharmaceuticals (Basel, Switzerland) · 2026
    Article
  20. Article

852 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 3 countries.

Alan L Harvey1] Research and Innovation Support, Dublin City University, Dublin 9, Ireland. [2] Strathclyde Institute of Pharmacy and Biomedical Science, University of Strathclyde, Glasgow G4 0NR, UK.
RuAngelie Edrada-EbelStrathclyde Institute of Pharmacy and Biomedical Science, University of Strathclyde, Glasgow G4 0NR, UK.
Ronald J QuinnEskitis Institute for Drug Discovery, Griffith University, Brisbane, Queensland 4111, Australia.
Dublin City University · IEGriffith University · AUUniversity of Strathclyde · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural products have been a rich source of compounds for drug discovery. However, their use has diminished in the past two decades, in part because of technical barriers to screening natural products in high-throughput assays against molecular targets. Here, we review strategies for natural product screening that harness the recent technical advances that have reduced these barriers. We also assess the use of genomic and metabolomic approaches to augment traditional methods of studying natural products, and highlight recent examples of natural products in antimicrobial drug discovery and as inhibitors of protein-protein interactions. The growing appreciation of functional assays and phenotypic screens may further contribute to a revival of interest in natural products for drug discovery.

Indexed as

AnimalsAnti-Infective AgentsBiodiversityBiological ProductsClinical Trials as TopicDrug DiscoveryDrug Evaluation, PreclinicalGenomicsHumansMolecular StructureAnti-Infective AgentsBiological Products

Identifiers

PMID25614221
OpenAlexW2088226047

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.